Similarly, SGLT2 inhibitors (SGLT2is) reduce the risk of CKD and HF through multiple physiological mechanisms; these include amelioration of tissue hypoxia, regulation of body weight, promotion of diuresis through glucosuria and natriuresis, and reduction of systemic blood pressure. The gene discussed is SLC5A2; the disease is chronic kidney disease.